Coca-Cola HBC AG said profit momentum carried into its latest guidance. The bottler forecasts further growth in organic operating profit as demand for non-alcoholic drinks remains steady across its Eu... ...

Some of the winners from that rush into AI drove the market higher on Monday. Chip companies rose, for example, with Nvidia up 2.4% and Broadcom up 3.3%. They were two of the strongest forces pushing the S&P 500 upward.Kroger climbed 3.9% after the grocer named a former Walmart executive as its new chief executive officer.Transocean reversed an early loss and rose 5.9% after the offshore drilling company said it would buy Valaris in an all-stock deal valued at $5.8 billion. Valaris leaped 34.3%.On the losi ...

Group 1 - The article discusses the potential for investors to position themselves in undervalued stocks that are mispriced by the market as February begins [1] - Stone Fox Capital, based in Oklahoma, is led by Mark Holder, a CPA with 30 years of investing experience, including 15 years as a portfolio manager [2] - The investing group "Out Fox The Street" provides stock picks, deep research, model portfolios, daily updates, real-time alerts, and community chat for investors [2] Group 2 - The article emphasizes the importance of conducting personal research or consulting a financial advisor before making investment decisions [4] - It highlights that past performance is not indicative of future results, and no specific investment recommendations are provided [5]

Core Viewpoint - The article emphasizes the importance of identifying undervalued stocks that are mispriced by the market, suggesting that investors should consider joining the investment group Out Fox The Street for insights and stock picks [1]. Group 1: Company Overview - Stone Fox Capital is an RIA based in Oklahoma, led by Mark Holder, a CPA with extensive experience in investing and portfolio management [2]. - Mark Holder has 30 years of investing experience, including 15 years as a portfolio manager, and leads the investing group Out Fox The Street [2]. Group 2: Investment Strategy - The investment group provides various features such as model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and community chat access for direct interaction with Mark [2]. - The focus is on uncovering potential multibaggers while managing portfolio risk through diversification [2].

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny.NYSE : HIMSHims & Hers HealthToday's Change( -16.07 %) $ -3.70Current Price$ 19.32Key Data PointsMarket Cap$5.2BDay's Range$ 16.36 - $ 19.5252wk Range$ 16.36 - $ 72.98Volume4.1MAvg Vol18MGross Margin65.40 %Hims & Hers Health (HIMS 16.07%), a direct-to-consumer telehealth platform, closed Monday at $19.33, down 16.03%. The stock dropped as news of a lawsuit from Novo Nordisk ...

Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursuing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a much lower starting price of $49. Hims & Hers Health stopped offering the medication on Saturday, following threats of legal action from the U.S. Food and Drug Administration (FDA) and Novo Nordisk. The FDA als ...

The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market. ...

Core Viewpoint - Hims & Hers Health is facing significant pressure due to regulatory concerns and a recent decision to cease offering its compounded semaglutide pill, leading to a substantial decline in stock value and revised revenue projections [1][2][3]. Group 1: Company Developments - Hims & Hers Health announced an expansion into weight loss by offering a compounded semaglutide pill at an introductory price of $49 for the first month [1]. - Following regulatory scrutiny, the company decided to stop offering the compounded semaglutide pill [2]. - The stock has fallen approximately 46% year-to-date, reflecting investor concerns [2]. Group 2: Analyst Insights - BofA Securities reduced the price forecast for Hims & Hers from $26 to $21, maintaining an Underperform rating due to increased risks associated with GLP-1 sales [3]. - Analyst Allen Lutz noted that the FDA's statements could lead to restrictions on GLP-1 active pharmaceutical ingredients, impacting both oral and injectable products [4]. - BofA has lowered GLP-1 revenue estimates by 25% for 2026, anticipating increased competition and a shift towards branded oral GLP-1s [7]. Group 3: Financial Projections - BofA estimates that Hims & Hers will generate $825-$850 million in injectable GLP-1 sales for fiscal 2025, with EBITDA margins around 10% [5]. - The company has narrowed its fiscal 2025 revenue outlook to between $2.335 billion and $2.355 billion, slightly above analyst estimates [6]. - The management's fourth-quarter revenue estimate is between $605 million and $625 million, below the analyst estimate of $631.68 million [6].

Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much uncertainty. HIMS stock is dropping. See the chart and price action here. Federal Crackdown: FDA & DOJOne catalyst for the crash was Hims’ recent aggressive attempt to launch a compounded oral semaglutide pill — a copycat of Novo Nordisk A/S’s (NYSE:NVO) newly approved oral Wegovy. The response from Washington was swift and severe:Under regulatory pressure, Hims & Hers did a U-turn on Saturday and announced it would stop o ...

Core Insights - Hims & Hers Health's stock dropped 25% after the company announced it would cease selling its compounded semaglutide weight-loss pill, just days after its launch, due to legal action from Novo Nordisk [1][1][1] - Novo Nordisk has filed a lawsuit against Hims & Hers, seeking to permanently ban the sale of unapproved compounded drugs that infringe on its patents and is pursuing damages [1][1][1] - Hims & Hers has faced significant stock depreciation, losing over 60% of its value in the past 12 months, while Novo Nordisk's shares have decreased by approximately 40% during the same period [1][1][1] Company Developments - Hims & Hers announced the discontinuation of its compounded weight-loss pill, which was marketed as having the same active ingredient as Novo Nordisk's Wegovy, following legal threats from Novo Nordisk [1][1][1] - The lawsuit from Novo Nordisk is described by Hims & Hers as a "blatant attack" on Americans who rely on compounded medications, indicating the company's intent to continue advocating for access to these treatments [1][1][1] Industry Context - The FDA has indicated plans to restrict the use of GLP-1 active ingredients in compounded weight-loss medications, specifically mentioning Hims & Hers in its statement [1][1][1] - Eli Lilly is anticipated to receive FDA approval for its own weight-loss pill later this year, which could further impact competition in the weight-loss drug market [1][1][1]